Hikma Pharmaceuticals Forecast, price target & analysts
Hikma Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Hikma Pharmaceuticals Classifications & Recommendation:
Hikma Pharmaceuticals Price Target
| Target Price | GBP26.11 |
| Price | GBP20.26 |
| Potential |
28.88%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Hikma Pharmaceuticals 2026 .
The average Hikma Pharmaceuticals target price is GBP26.11.
This is
28.88%
register free of charge
GBP32.55
60.66%
register free of charge
GBP21.21
4.69%
register free of charge
|
|
| A rating was issued by 19 analysts: 16 Analysts recommend Hikma Pharmaceuticals to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hikma Pharmaceuticals stock has an average upside potential 2026 of
28.88%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion GBP | 2.30 | 2.48 |
| 9.77% | 7.89% | |
| EBITDA Margin | 22.85% | 26.44% |
| 7.49% | 15.73% | |
| Net Margin | 11.38% | 15.39% |
| 72.13% | 35.30% |
13 Analysts have issued a sales forecast Hikma Pharmaceuticals 2025 . The average Hikma Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Hikma Pharmaceuticals EBITDA forecast 2025. The average Hikma Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Hikma Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Hikma Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share GBP | 1.17 | 1.72 |
| 88.71% | 47.01% | |
| P/E | 11.77 | |
| EV/Sales | 2.10 |
13 Analysts have issued a Hikma Pharmaceuticals forecast for earnings per share. The average Hikma Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Hikma Pharmaceuticals...
Current Hikma Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Jan 29 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Jan 29 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
